TrialFrontiers in immunology2022

Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3-9-month intervals following two-dose inactivated vaccine (CoronaVac).

Yuting Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.